Skip to main content

Latest stock market podcasts

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Weekly Wrap 9 April

Bell Direct
April 9, 2020

Market Update 8 April

Bell Direct
April 8, 2020

Morning Bell 7 April

Bell Direct
April 7, 2020

Morning Bell 6 April

Bell Direct
April 6, 2020

Weekly Wrap 3 April

Bell Direct
April 3, 2020

Market Update 2 April

Bell Direct
April 2, 2020

Market Update 1 April

Bell Direct
April 1, 2020

March Market Overview

Bell Direct
March 31, 2020

Market Update 31 March

Bell Direct
March 31, 2020

Weekly Wrap 27 March

Bell Direct
March 27, 2020

Morning Bell 24 March

Bell Direct
March 24, 2020

Morning Bell 23 March

Bell Direct
March 23, 2020